A
panel of medical experts are due to meet later in the day to
decide on a recommendation for the Pfizer-BioNTech coronavirus
vaccine to receive emergency use authorization from the U.S.
Food and Drug Administration.
Some officials said vaccinations could begin as soon as this
weekend if the FDA consented. Pfizer's shares rose 0.4% before
the bell.
Wall Street's main indexes have scaled record highs in the past
few weeks as investors bet on a vaccine-linked economic recovery
and shrugged off glum macroeconomic data showing the near-term
impact from sweeping coronavirus-induced lockdowns.
The latest such indicator, the weekly jobless claims report, is
due at 8:30 a.m. ET on Thursday and is expected to show 725,000
applications for the week ended Dec. 5, compared with 712,000 in
the prior week.
Investors are also keeping an eye out for signs of more fiscal
stimulus to speed up the labor market's recovery.
U.S. lawmakers approved a stopgap government funding bill on
Wednesday that would provide more time for negotiations, but an
agreement has remained elusive due to disagreements over aid to
state and local governments and business liability protections.
"The worsening pandemic in late 2020 calls for a new crisis
package (and) we think Congress will agree on additional
spending by then, but it is a close call," analysts at Standard
Chartered Bank wrote in a note.
At 06:50 a.m. ET, Dow E-minis were up 41 points, or 0.14%, S&P
500 E-minis were up 2 points, or 0.05%, and Nasdaq 100 E-minis
were down 15.5 points, or 0.13%.
Global market sentiment was a little more downbeat after S&P Dow
Jones Indices said it would remove 10 Chinese companies from its
equities indices following a Trump administration order to
prohibit purchases by U.S. investors of certain Chinese
securities.
Among individual stocks, Facebook Inc fell 1%, extending
declines from the previous session.
The social media company could be forced to sell its prized
assets WhatsApp and Instagram after the Federal Trade Commission
and nearly every U.S. state filed lawsuits against it.
(Reporting by Shriya Ramakrishnan in Bengaluru; Editing by
Shounak Dasgupta)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|